NCT05815290View on ClinicalTrials.gov

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

March 30, 2026

Conditions
dMMR Colorectal Cancer
Interventions
DRUG

Cadonilimab

Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles

Trial Locations (1)

Unknown

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER